What we do - MyCartis

Discover Evalution^®

With Evalution^® you find more
clinical information faster

Join our partners

Drug development solutions

For pharma customers we co-develop your companion Diagnostic Assay
Service Lab partnering

To provide your customers with novel solutions in Assay development

Integrated solutions

Integrate our DMAT^® technology as reader inside your own IVD platform
Porting novel biomarkers on the platform

We partner with biomarker discovery companies and port their panels on our Evalution^® platform

Partner quotes

"The unique combination of multiplexing, sensitivity and flexibility turns the Evalution platform into an indispensable tool for the life science R&D market"

Dr.Ir. Karen Leirs
Postdoctoral Researcher
KU Leuven Biosensors group

"Thanks to the characteristics of the microflow, creations of novel or specialized immunoassays are just as easy as running conventional ones. Together with the flexibility of the particles, Evalution offers a solution not met elsewhere."

Maja Neiman, Ph.D.
Head of Autoimmunity Profiling Facility
Affinity Proteomics, SciLifeLab, Stockholm
KTH - Royal Institute of Technology

Let’s connect!

Clinical domains which are relevant for MyCartis’ technology

Oncology
Serology
Immunology
Other

Assays in development

Adverse events in immuno-oncology

When evolving from research to clinical application of immune-oncology therapy, real-time follow-up of patients is of essence. Adverse events need to be detected, managed and followed up as early and effective as possible in order to optimize the therapeutic effect. MyCartis develops a real-time patient and therapy monitoring assay to follow up on Cytokine Release Syndrome (CRS).

Donor organ assessment for more efficient transplantation

Better and more effective management and selection of fit-for-purpose donor organs is key and requires fast assessment. MyCartis builds a real-time inflammation assay to objectively assess and select organs for successful transplantation.

DMAT^® Technology

Dynamic Multi-Analyte Technology (DMAT®) offers simultaneous end-point and real-time measurement of multiple biomarkers with minimum assay variability. It supports a variety of assay formats, such as sandwich assays for measuring biomarkers and (in)direct assays for quantifying specific antibodies in samples.

Evalution® is an integrated system based on three elements: the instrument, the disposable: cartridge with micro-particles inside and the software containing advanced analysis algorithms. No additional equipment is required.

Download PDF for more information

Instrument

Cartridge with encoded microparticles

Software and data analysis algorithms

Evalution^® Platform Configurations

MyCartis’ proprietary platform Evalution^® is powered by DMAT^®. It brings all the DMAT^® benefits and features, such as ultra-fast real-time assays and minimal assay variability. Evalution® comes in 3 different configurations, each designed to provide a unique solution to life science R&D, clinical research and routine clinical diagnostics respectively.

Menu

Discover Evalution®

Ultra-fast

Dynamic range

Sample volume

Binding strength

Multiplexing

On Evalution®, multiplex biomarker assays can be run using conventional as well as next-generation immunoassay workflows, both resulting in short assays. Building on our unique capability of real-time reaction monitoring, multiplex biomarker assays can be run within 15 minutes.

Next to the conventional end-point measurement, Evalution® quantifies biomarkers based on their real-time binding curve. As this signal is hard to saturate, virtually unlimited dynamic ranges of biomarker concentrations can be measured without additional or multiple dilution steps.

In Evalution®, binding reactions occur fast, in a microfluidic channel. Therefore, you just need microliters of a clinical sample to allow multiplex biomarker assessment.

Easy, reliable and efficient multiplex assays ranging from one to several tens of biomarkers.

Join our partners

Drug development solutions

Service Lab partnering

Integrated solutions

Porting novel biomarkers on the platform

Partner quotes

Let’s connect!

Clinical domains which are relevant for MyCartis’ technology

Oncology

Serology

Immunology

Other

Diagnostic solutions are applied at different time points within the "disease cycle": pre/post diagnosis, pre/during/post therapy, pre/post curing. Evalution® is an attractive and comprehensive solution to deploy in this space, especially because short turnaround times are increasingly relevant.

Download PDF for more information

Assays in development

Adverse events in immuno-oncology

Donor organ assessment for more efficient transplantation

DMAT® Technology

Download PDF for more information

Instrument

Cartridge with encoded microparticles

Software and data analysis algorithms

The instrument provides precise temperature and fluidic control to minimize assay run-to-run variability. It is equipped with advanced optics for real-time measurement of the fluorescence signals from the assays.

Using advanced image processing and data analysis algorithms, DMAT® captures the fluorescence signals on the microparticles in real-time and converts the raw data to relevant information such as target concentration and binding strength.

Evalution® Platform Configurations

Evalution® Research & Development

Evalution® Automation

Evalution® Clinical Diagnostics

The Research & Development configuration offers maximum flexibility on immunoassay designs and workflows for a variety of life science applications. Supports end-point and real-time immunoassays

The Automation configuration offers a fully automated solution to meet your clinical research workflow needs.

The Clinical Diagnostics configuration (in development) addresses the low to medium throughput needs of clinical laboratories.

Contact

MyCartis NV

Stay tuned

Get directions

Discover Evalution^®

On Evalution^®, multiplex biomarker assays can be run using conventional as well as next-generation immunoassay workflows, both resulting in short assays. Building on our unique capability of real-time reaction monitoring, multiplex biomarker assays can be run within 15 minutes.

Next to the conventional end-point measurement, Evalution^® quantifies biomarkers based on their real-time binding curve. As this signal is hard to saturate, virtually unlimited dynamic ranges of biomarker concentrations can be measured without additional or multiple dilution steps.

In Evalution^®, binding reactions occur fast, in a microfluidic channel. Therefore, you just need microliters of a clinical sample to allow multiplex biomarker assessment.

Diagnostic solutions are applied at different time points within the "disease cycle": pre/post diagnosis, pre/during/post therapy, pre/post curing.

Evalution^® is an attractive and comprehensive solution to deploy in this space, especially because short turnaround times are increasingly relevant.

DMAT^® Technology

Evalution^® Platform Configurations

Evalution^® Research & Development

Evalution^® Automation

Evalution^® Clinical Diagnostics

The Research & Development configuration offers maximum flexibility on immunoassay designs and workflows for a variety of life science applications.

Supports end-point and real-time immunoassays